Regulatory & Compliance

Review of Modeyso Brain Cancer Treatment
Research & Development Review of Modeyso Brain Cancer Treatment

Imagine a diagnosis so devastating that it offers a median survival of just one year, primarily striking children and young adults with little hope for effective intervention. Diffuse midline glioma with an ### K27M mutation, an ultra-rare and aggressive brain cancer, affects roughly 2,000

Epcoritamab Shines in Phase 3 Trial for Follicular Lymphoma
Research & Development Epcoritamab Shines in Phase 3 Trial for Follicular Lymphoma

What happens when a relentless cancer, deemed incurable, meets a groundbreaking therapy that defies the odds? For the 15,000 Americans diagnosed annually with follicular lymphoma—a slow-growing but persistent form of non-Hodgkin lymphoma—this question is no longer hypothetical. A stunning phase 3

Can Tremfya Redefine Psoriatic Arthritis Treatment?
Research & Development Can Tremfya Redefine Psoriatic Arthritis Treatment?

Welcome to an insightful conversation with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the exciting news surrounding Johnson & Johnson’s recent

FDA Approves Empaveli for Rare Kidney Diseases in US
Management & Regulatory FDA Approves Empaveli for Rare Kidney Diseases in US

Imagine a world where thousands of Americans, including children, face the grim reality of kidney failure within a decade due to rare, debilitating conditions like C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These diseases, affecting around

Biktarvy Gains FDA Approval for Broader HIV Treatment Use
Management & Regulatory Biktarvy Gains FDA Approval for Broader HIV Treatment Use

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent FDA approval of Gilead Sciences’ Biktarvy for expanded HIV

FDA Approves Sephience for Rare PKU Disorder Treatment
Management & Regulatory FDA Approves Sephience for Rare PKU Disorder Treatment

Imagine living with a condition where even a small bite of protein-rich food could lead to severe neurological damage, a daily reality for thousands of individuals in the U.S. diagnosed with phenylketonuria (PKU), a rare genetic metabolic disorder. Affecting approximately one in every 13,500 to

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later